Steroid
( DrugBank: - / KEGG DRUG: - )
4 diseases
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 95 | Autoimmune hepatitis | 8 |
| 107 | Juvenile idiopathic arthritis | 8 |
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 222 | Primary nephrotic syndrome | 128 |
| 288 | Autoimmune acquired coagulation factor deficiency | 1 |
95. Autoimmune hepatitis
Clinical trials : 63 / Drugs : 80 - (DrugBank : 30) / Drug target genes : 24 - Drug target pathways : 116
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|
107. Juvenile idiopathic arthritis
Clinical trials : 500 / Drugs : 338 - (DrugBank : 52) / Drug target genes : 65 - Drug target pathways : 157
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|
222. Primary nephrotic syndrome
Clinical trials : 576 / Drugs : 519 - (DrugBank : 130) / Drug target genes : 108 - Drug target pathways : 219
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|
288. Autoimmune acquired coagulation factor deficiency
Clinical trials : 35 / Drugs : 45 - (DrugBank : 11) / Drug target genes : 8 - Drug target pathways : 19
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|